Skip to main content

NCBiotech News

  • Oxygen Biotherapeutics is drawing attention from investors, consumers and job seekers. The pharmaceutical company has expanded quickly since relocating its headquarters from California to Durham a year ago. Earlier this year it started trading on the NASDAQ stock market, where it opened this week with a jump of as much as one-third since last week's close. It now has 13 people at its Durham headquarters, and it's actively adding more.
  • Bio Briefs with names making news
  • Fayetteville State University is throwing a seriously scientific party for one of its prized scientists this Friday. Valeria Fleming, Ph.D., who has served FSU as a biology and biotechnology professor for 50 years, is to be honored with a free public science colloquium, Biology/Biotechnology: Linking the Past to the Future for our Students. It's at 2 p.m. in the campus' Seabrook Auditorium.
  • North Carolina women historically have more preterm births than the national average. And the state's infant mortality rate has also exceeded the American average. Now, thanks to a $151,246 Institutional Development Grant from the North Carolina Biotechnology Center, an interdisciplinary team of Appalachian State University researchers is buying lab equipment to study the preterm birth situation.
  • Today you can own a piece of a company that might someday recreate a piece of you. Pennsylvania-based Tengion, the high-profile regenerative medicine firm with a research office, a development laboratory and a pilot manufacturing facility in Winston-Salem, launches its initial public offering of stock today on the NASDAQ exchange under the symbol TNGN. The firm expected to sell six million shares, with an opening price of $5 a share.
  • The Hamner Institutes for Health Sciences will get $5 million from Dow Chemical Co. to computerize chemical safety data. The five-year grant targets a Hamner program that tests chemical toxicity using human cells and high-speed computers.
  • Research Triangle Park-based public biopharmaceutical company Icagen hopes to raise some $25 million from outsiders. The 18-year-old clinical-stage firm has filed a shelf offering with the Securities and Exchange Commission, indicating plans to raise the money through sales of stock and/or through other means.
  • Pittsboro-based Biolex Therapeutics has announced positive results for its lead drug candidate, a new form of interferon to battle hepatitis C. The firm is developing a controlled-release interferon product, Locteron, to treat chronic hepatitis C. It's using duckweed -- a plant that can often be found on the surface of ponds -- to produce the protein needed for the medicine.
  • Bio Briefs with names making news
  • Four North Carolina metro areas are among the top 25 places for doing business, according to recent rankings by The Raleigh metro area ranked third, and the Charlotte area came in 17th when scored by three criteria: cost of doing business, job growth projected and educational attainment. Asheville was # 21 and Durham 23.
  • There's not a dry eye in the house for the folks at Durham-based Inspire Pharmaceuticals since they finally got some good news about one of their dry-eye treatments. Inspire and Osaka, Japan-based Santen Pharmaceutical Co. have issued a joint announcement saying Japanese health officials have approved the marketing of an Inspire-developed therapy, diquafosol tetrasodium ophthalmic solution.
  • Forsyth Technical Community College's foresight in embracing biotechnology won the institution $20,000 last weekend. Forsyth Tech President Gary Green, Ed.D., brought the check home from Seattle, where he was attending the 2010 conference of the American Association of Community Colleges.
  • Amber Shirley is on a mission to help North Carolina farms and farmers thrive. This week the Ph.D. research scientist joined the North Carolina Biotechnology Center in the newly created position of Biotechnology Crops Development Director. She reports to Gwyn Riddick, M.B.A., vice president of agricultural biotechnology.
  • Eight years ago the North Carolina Biotechnology Center put nearly $60,000 into Harold Kohn's epilepsy research quest at the University of North Carolina at Chapel Hill.
  • Loans of more than $400,000 from the North Carolina Biotechnology Center are starting to pay off for Arbovax, a fledgling vaccine developer. Arbovax, the Raleigh-based spinout from North Carolina State University, will start preclinical testing of its unique new Dengue fever vaccine in early May. Dengue is ranked second only to Malaria by the World Health Organization, for its devastating global impact.
  • A UNC technology designed to make breathing easier hit the big time this week when Oriel Therapeutics got a buy-out offer from Sandoz, the generics division of Novartis.
  • Bio Briefs with names making news
  • It's only money. Who needs it? Sunday, May 2, is the deadline for discounted conference hotel rates for the 12th Annual NIH SBIR Conference in Raleigh. The event, to run June 2 and 3 at the Raleigh Convention Center, will feature more than 50 representatives of the National Institutes of Health with more than $690 million in grant funding to distribute.
  • About a quarter of a million people in North Carolina make their living because of biotechnology. This according to a study released today by BIO and the Battelle organization. North Carolina, at the end of 2008, had more than 53,000 people employed in biotechnology. The ripple effects of those jobs brings the total to 247,457 That's 4.62 jobs for each biotech job. In addition, bioscience jobs command a high salary on average, and even technician-level jobs pay higher than jobs with similar qualifications.
  • North Carolina will share its experiences and expertise in finance, international partnerships, devices, biologics and diagnostics Wednesday at the BIO 2010 International Convention. The 10 speakers will participate in: The Global Innovation Network - International Case Studies 3:00 PM S101B John Chaffee, North Carolina Eastern Region


Subscribe to News & Events